CL2004000392A1 - Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra - Google Patents

Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Info

Publication number
CL2004000392A1
CL2004000392A1 CL200400392A CL2004000392A CL2004000392A1 CL 2004000392 A1 CL2004000392 A1 CL 2004000392A1 CL 200400392 A CL200400392 A CL 200400392A CL 2004000392 A CL2004000392 A CL 2004000392A CL 2004000392 A1 CL2004000392 A1 CL 2004000392A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
compounds
trisustituidos
dislipidemia
oxazol
Prior art date
Application number
CL200400392A
Other languages
English (en)
Spanish (es)
Inventor
Kirk Glombik Heiner Fa Gretzke
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of CL2004000392A1 publication Critical patent/CL2004000392A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
CL200400392A 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra CL2004000392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
CL2004000392A1 true CL2004000392A1 (es) 2005-04-22

Family

ID=32920629

Family Applications (2)

Application Number Title Priority Date Filing Date
CL200400392A CL2004000392A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
CL200400391A CL2004000391A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL200400391A CL2004000391A1 (es) 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Country Status (34)

Country Link
US (5) US7259177B2 (US07259177-20070821-C00218.png)
EP (3) EP1599452B1 (US07259177-20070821-C00218.png)
JP (3) JP2006519193A (US07259177-20070821-C00218.png)
KR (3) KR20050106461A (US07259177-20070821-C00218.png)
CN (3) CN100398526C (US07259177-20070821-C00218.png)
AR (3) AR043427A1 (US07259177-20070821-C00218.png)
AT (3) ATE365159T1 (US07259177-20070821-C00218.png)
AU (3) AU2004215673B2 (US07259177-20070821-C00218.png)
BR (3) BRPI0407758A (US07259177-20070821-C00218.png)
CA (3) CA2517381A1 (US07259177-20070821-C00218.png)
CL (2) CL2004000392A1 (US07259177-20070821-C00218.png)
CO (2) CO5690580A2 (US07259177-20070821-C00218.png)
DE (4) DE10308355A1 (US07259177-20070821-C00218.png)
DK (3) DK1599455T3 (US07259177-20070821-C00218.png)
EC (2) ECSP055985A (US07259177-20070821-C00218.png)
ES (3) ES2326418T3 (US07259177-20070821-C00218.png)
HR (3) HRP20050743A2 (US07259177-20070821-C00218.png)
IL (2) IL170316A (US07259177-20070821-C00218.png)
MA (3) MA27736A1 (US07259177-20070821-C00218.png)
MX (3) MXPA05008951A (US07259177-20070821-C00218.png)
NO (3) NO20054408L (US07259177-20070821-C00218.png)
OA (2) OA13035A (US07259177-20070821-C00218.png)
PA (1) PA8596801A1 (US07259177-20070821-C00218.png)
PE (3) PE20040959A1 (US07259177-20070821-C00218.png)
PL (3) PL378437A1 (US07259177-20070821-C00218.png)
PT (3) PT1599455E (US07259177-20070821-C00218.png)
RS (1) RS20050594A (US07259177-20070821-C00218.png)
RU (3) RU2005129992A (US07259177-20070821-C00218.png)
SA (1) SA04250153A (US07259177-20070821-C00218.png)
TN (2) TNSN05204A1 (US07259177-20070821-C00218.png)
TW (3) TW200508210A (US07259177-20070821-C00218.png)
UY (2) UY28210A1 (US07259177-20070821-C00218.png)
WO (3) WO2004076428A1 (US07259177-20070821-C00218.png)
ZA (2) ZA200505765B (US07259177-20070821-C00218.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039532B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
US8128969B2 (en) 2006-08-10 2012-03-06 Mimozax Co., Ltd. Hypoglycemic composition containing acacia bark derivative
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
CN103435593B (zh) 2008-02-29 2015-01-28 日产化学工业株式会社 噻吩化合物及其中间体的制造方法
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
CN116224736A (zh) 2017-12-13 2023-06-06 佳能株式会社 盒与图像形成装置
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP0876379A1 (en) 1996-01-17 1998-11-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
IL142649A (en) 1996-12-31 2004-12-15 Reddy Research Foundation Azole derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
BR9810592A (pt) 1997-07-16 2000-09-12 Novo Nordisk As Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
KR100620337B1 (ko) * 1998-03-10 2006-09-13 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) * 1998-08-27 2003-12-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
EP1173438A1 (en) 1999-04-16 2002-01-23 Novo Nordisk A/S Substituted imidazoles, their preparation and use
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
CN1183113C (zh) * 1999-04-28 2005-01-05 阿文蒂斯药物德国有限公司 作为ppar受体配体的三芳基酸衍生物
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
CA2376919C (en) 1999-06-18 2008-11-04 Merck & Co., Inc. Arylthiazolidinedione and aryloxazolidinedione derivatives
JP2003504082A (ja) 1999-07-09 2003-02-04 コヘージョン テクノロジーズ， インコーポレイテッド エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
US6967201B1 (en) 1999-07-29 2005-11-22 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
PL353367A1 (en) 1999-09-01 2003-11-17 Aventis Pharma Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
PL357118A1 (en) 1999-12-03 2004-07-12 Astrazeneca Ab Crystalline form of (s)-2 ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid
DK1283735T4 (da) 2000-03-31 2013-02-04 Royalty Pharma Collection Trust Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf
EP1277745A4 (en) 2000-04-25 2004-09-15 Kyorin Seiyaku Kk NEW STABLE CRYSTALS OF THIAZOLIDINDION DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
DE60129806T2 (de) 2000-04-28 2007-12-06 Asahi Kasei Pharma Corp. Neue bizyklische verbindungen
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
CA2410597A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
PT1294682E (pt) 2000-06-09 2004-09-30 Aventis Pharma Gmbh Derivados de acilfenilureia processo para a sua preparacao e sua aplicacao como medicamentos
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
NZ523804A (en) * 2000-08-23 2004-09-24 Lilly Co Eli Peroxisome proliferator activated receptor agonists
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
JPWO2002046146A1 (ja) 2000-12-05 2004-04-08 杏林製薬株式会社 置換カルボン酸誘導体
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1345895B1 (de) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
ATE370130T1 (de) * 2000-12-25 2007-09-15 Ono Pharmaceutical Co Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
PL367077A1 (en) * 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003005025A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
RU2330846C2 (ru) 2001-08-31 2008-08-10 Санофи-Авентис Дойчланд Гмбх Диарилциклоалкильные производные, способ их получения и их применение в качестве ppar-активаторов
WO2003066581A1 (en) 2002-02-05 2003-08-14 Eli Lilly And Company Urea linker derivatives for use as ppar modulators
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
IL164249A0 (en) 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
PT1599453E (pt) 2009-07-14
CO5690578A2 (es) 2006-10-31
ES2287700T3 (es) 2007-12-16
AR043432A1 (es) 2005-07-27
ATE365159T1 (de) 2007-07-15
JP2006519194A (ja) 2006-08-24
AU2004215677B2 (en) 2010-01-07
OA13035A (en) 2006-11-10
ES2326418T3 (es) 2009-10-09
CL2004000391A1 (es) 2005-01-07
PL378437A1 (pl) 2006-04-03
TW200500349A (en) 2005-01-01
RS20050594A (en) 2007-12-31
BRPI0407758A (pt) 2006-02-14
PT1599455E (pt) 2009-09-29
HRP20050742A2 (en) 2006-09-30
MXPA05008951A (es) 2005-11-04
UY28209A1 (es) 2004-09-30
BRPI0407907A (pt) 2006-02-14
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
EP1599453A1 (de) 2005-11-30
AR043433A1 (es) 2005-07-27
ZA200505765B (en) 2006-05-31
MXPA05008988A (es) 2005-10-18
EP1599455A1 (de) 2005-11-30
JP2006519199A (ja) 2006-08-24
US7335671B2 (en) 2008-02-26
RU2005130002A (ru) 2006-01-27
EP1599453B1 (de) 2009-05-06
MXPA05008995A (es) 2005-10-18
EP1599452A1 (de) 2005-11-30
US20040209920A1 (en) 2004-10-21
DK1599453T3 (da) 2009-08-24
ECSP055986A (es) 2006-01-16
CA2517386A1 (en) 2004-09-10
RU2005129992A (ru) 2006-02-10
DK1599452T3 (da) 2007-10-01
JP2006519193A (ja) 2006-08-24
OA13034A (en) 2006-11-10
CA2516620A1 (en) 2004-09-10
PL377735A1 (pl) 2006-02-20
US20050101637A1 (en) 2005-05-12
ATE435217T1 (de) 2009-07-15
NO20054396L (no) 2005-11-11
PT1599452E (pt) 2007-09-12
MA27736A1 (fr) 2006-02-01
EP1599452B1 (de) 2007-06-20
DE502004004139D1 (de) 2007-08-02
CN1753881A (zh) 2006-03-29
HRP20050744A2 (en) 2006-09-30
US7365084B2 (en) 2008-04-29
CN100439347C (zh) 2008-12-03
KR20050106461A (ko) 2005-11-09
SA04250153A (ar) 2005-12-03
US7259177B2 (en) 2007-08-21
DE502004009453D1 (de) 2009-06-18
PE20050292A1 (es) 2005-05-24
PE20050293A1 (es) 2005-05-24
US20080167354A1 (en) 2008-07-10
BRPI0407814A (pt) 2006-02-14
ZA200505768B (en) 2005-11-23
KR20050105492A (ko) 2005-11-04
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
CN1756748A (zh) 2006-04-05
DE502004009690D1 (de) 2009-08-13
CN100439345C (zh) 2008-12-03
WO2004076428A1 (de) 2004-09-10
WO2004076426A1 (de) 2004-09-10
TNSN05206A1 (en) 2007-06-11
WO2004076427A1 (de) 2004-09-10
AU2004215672A1 (en) 2004-09-10
CA2517381A1 (en) 2004-09-10
DE10308355A1 (de) 2004-12-23
ECSP055985A (es) 2006-01-16
TNSN05204A1 (en) 2007-06-11
AU2004215672B2 (en) 2010-01-07
IL170314A (en) 2010-11-30
MA27737A1 (fr) 2006-02-01
PE20040959A1 (es) 2005-01-17
ATE430738T1 (de) 2009-05-15
AR043427A1 (es) 2005-07-27
EP1599455B1 (de) 2009-07-01
US20050215596A1 (en) 2005-09-29
UY28210A1 (es) 2004-09-30
MA27742A1 (fr) 2006-02-01
PL378130A1 (pl) 2006-03-06
NO20054398L (no) 2005-11-02
CN100398526C (zh) 2008-07-02
US7872034B2 (en) 2011-01-18
KR20050106462A (ko) 2005-11-09
CO5690580A2 (es) 2006-10-31
AU2004215673B2 (en) 2009-10-01
AU2004215677A1 (en) 2004-09-10
NO20054396D0 (no) 2005-09-22
TW200510352A (en) 2005-03-16
RU2005129995A (ru) 2006-01-27
NO20054408D0 (no) 2005-09-22
ES2329366T3 (es) 2009-11-25
TW200508210A (en) 2005-03-01
NO20054398D0 (no) 2005-09-22
DK1599455T3 (da) 2009-11-09
CN1753879A (zh) 2006-03-29
AU2004215673A1 (en) 2004-09-10
US20080015238A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
CL2004000392A1 (es) Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
DE60138872D1 (de) Azetidinderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
DE60225331D1 (de) Pharmazeutische zusammensetzungen mit metformin und glibenclamid zur behandlung von diabetes mellitus typ ii
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
DE60014918D1 (de) Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
BR9711098B1 (pt) compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos e seu uso no tratamento de diabetes e doenças relacionadas.
BRPI0407755B1 (pt) composiÇço catalÍtica, sua preparaÇço e uso
DE60131703D1 (de) Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
IL183982A0 (en) Controlled release formulation for oral administration for treating diabetes containing metformin and methods for the preparation thereof
EE05269B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad ravimid, nende kasutamine ja meetodid nende valmistamiseks
CL2008003153A1 (es) Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras.
EE200400001A (et) alfa-metoksütsinnamaadid, nende valmistamine ja kasutamine peroksisoomi proliferaator-aktiveeritud retseptorite moduleerimiseks ning neid sisaldavad ravimkompositsioonid
BRPI0415825A (pt) novos derivados de tetrahidroespiro{piperidino-2,7'-pirrol[3,2b]piridina } e novos derivados de indol úteis no tratamento de distúrbios relacionados ao receptor 5-ht6
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
HUP0204557A3 (en) Benzazole derivatives, their use as jnk modulators, their preparation and pharmaceutical compositions containing them
NO20011503L (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
CL43489B (es) Compuestos derivados de difenilazetidinona y su sal farmaceuticamente aceptable; composicion faramceutica; compuestos intermediarios; procedimiento para preparar la composicion farmaceutica; y uso de los compuestos para tratar la hiperlipidemia, sint
ITMI20021427A0 (it) Composizioni per uso nell'alimentazione animale comprendente una matrice a rilascio controllato procedimento di preparazione e relativo impi
EE200200399A (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend